T-TAs® 01 as a new tool for the evaluation of hemostasis in thrombocytopenic patients after platelet transfusion
Sanz, Cristina (Banc de Sang I Teixits)
Escolar, Ginès (Institut d'Investigacions Biomèdiques August Pi i Sunyer)
Diaz-Ricart, Maribel (Institut d'Investigacions Biomèdiques August Pi i Sunyer)
Samanbar, Sahar (Universitat de Barcelona)
Piñeyroa, Juan A. (Hospital Clínic i Provincial de Barcelona)
Moreno-Castaño, Ana B. (Institut d'Investigacions Biomèdiques August Pi i Sunyer)
Pino, Marc (Institut d'Investigacions Biomèdiques August Pi i Sunyer)
Torramadé-Moix, Sergi (Institut d'Investigacions Biomèdiques August Pi i Sunyer)
Martinez-Sanchez, Julia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Lozano, Miquel (Hospital Clínic i Provincial de Barcelona)

Date:	2024
Abstract:	background - Current laboratory tests fail to evaluate the hemostatic function of platelets in patients with thrombocytopenia. We investigated the use of the Total Thrombus-Formation Analysis System (T-TAS® 01 [Fujimori Kogyo Co, Tokyo, Japan]) to evaluate hemostasis under conditions of experimental thrombocytopenia, and in patients before and after platelet transfusion. materials and methods - Specific T-TAS 01 chips, for thrombocytopenic conditions, were used. The area under the curve (AUC) and occlusion time (OT, min) were measured in: (i) experimentally induced thrombocytopenia (183±15 to 6. 3±1. 2×10 platelets/µL) in blood samples from healthy donors (No. =13), and (ii) blood from oncohematological thrombocytopenic patients (No. =48), before and after platelet transfusion. The influences of hematocrit and number of transfusions were analyzed in these patients. results - Progressive reductions of AUC and prolongations of OT related significantly to decreasing platelet counts (p<0. 05 for all) in experimental thrombocytopenia. In samples from thrombocytopenic patients, platelet counts, AUC and OT were, respectively, 10. 8±0. 6×10/µL, 175. 2±59, and 27. 2±1 min before transfusion; and 22±1. 5×10/µL, 400. 8±83 and 22. 9±1. 5 min after platelet transfusion (p<0. 01 for all). A hematocrit below 25% or exposure to ten or more previous platelet transfusions had a negative impact on the T-TAS 01 performance in patients. In vitro correction of the hematocrit improved the hemostatic response in thrombocytopenic patients. discussion - T-TAS 01 measurements were sensitive to low platelet counts in the experimental setting. The technology was sensitive to evaluate the hemostatic capacity of platelet transfusions. Exposure to multiple medications, repeated platelet transfusions and lower hematocrits may interfere with the hemostatic performance in oncohematological patients with thrombocytopenia.
Grants:	Instituto de Salud Carlos III PI19/00888 "la Caixa" Foundation 202026-10 Agència de Gestió d'Ajuts Universitaris i de Recerca 2017/SGR-675
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Thrombocytopenia ; Total thrombus-formation analysis system (T-TAS) ; Platelet transfusion ; Bleeding
Published in:	Blood Transfusion, Vol. 22 Núm. 2 (march 2024) , p. 166-175, ISSN 2385-2070

DOI: 10.2450/BloodTransfus.550
PMID: 38063791

10 p, 1.9 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP) > Josep Carreras Leukaemia Research Institute
Articles > Research articles
Articles > Published articles